The first-in-human trial of glycocalyx-edited autologous MSCs shows that engineering bone homing via sLeX expression reduces fragility fractures and increases bone density in advanced osteoporosis patients, with five-plus years of safety data and no serious adverse events.
Multiple 2026 clinical trials and reviews show mesenchymal stem cell therapy is safe and feasible for Parkinson's disease — but what do the actual data say about efficacy, dosing, and what comes next?
A 2025 meta-analysis of 52 studies, real-world Taiwan data, and Mayo Clinic intraarterial delivery results — what nephrologists need to know about MSCs and CKD.
The 2026 evidence base for mesenchymal stem cell therapy in ischemic stroke includes a 26-study umbrella review and an 18-RCT network meta-analysis of 1,006 patients. MSCs were the only cell type to significantly reduce mortality. This medical review synthesizes the latest clinical data, mechanisms, active trials, and translational barriers.
A 2026 meta-analysis of 15 RCTs shows MSCs cut acute GvHD incidence by 53% and chronic GvHD by 50%. A biomarker-guided trial identifies which transplant patients benefit most — and a cell-free exosome approach may be next.
A technical deep dive into MSC immunomodulation for autoimmune disease: Treg induction, macrophage polarization, and clinical evidence from the SMART-MS trial.
Russian 
English 
Chinese 
French